{"id":"W1740796324","doi":"10.1111/j.1755-5922.2011.00281.x","title":"The Future of Anticoagulant Therapy","year":2011,"lang":"en","type":"editorial","venue":"Cardiovascular Therapeutics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rivaroxaban; Apixaban; Dabigatran; Fondaparinux; Direct thrombin inhibitor; Discovery and development of direct thrombin inhibitors; Ximelagatran; Intensive care medicine; Vitamin K antagonist; Anticoagulant; Warfarin; Atrial fibrillation; Pharmacology; Surgery; Thrombosis; Thrombin; Internal medicine; Venous thromboembolism","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000935209,0.0003580025,0.001111822,0.0000948122,0.0001496463,0.00003673553,0.0003344912,0.0006852362,0.00002341013],"category_scores_gemma":[0.00004879694,0.0002105407,0.002589756,0.000208916,0.0001698811,0.0000327647,0.00007287156,0.000500768,0.00002562049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004378929,"about_ca_system_score_gemma":0.000207533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001036067,"about_ca_topic_score_gemma":0.000001336052,"domain_scores_codex":[0.9974216,0.0001727281,0.0004831162,0.0003256257,0.00129987,0.0002971089],"domain_scores_gemma":[0.9973618,0.0003128941,0.0002416162,0.001542711,0.0004785908,0.00006239227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009018541,0.0000243184,0.0008947671,0.0003315927,0.03624931,0.00003779134,0.0003021349,0.000008156912,0.00009956148,0.0009086505,0.5797432,0.3804987],"study_design_scores_gemma":[0.001638277,0.000138507,0.0006967197,0.00005660399,0.002499191,0.000003531443,0.0000827955,0.000005520068,0.0002786384,0.0001634924,0.9942186,0.0002180716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0002314244,0.2447012,0.0002639907,0.0002876332,0.7516384,0.0009124394,0.00002194755,0.00007562872,0.001867434],"genre_scores_gemma":[0.001021731,0.1787818,0.0001293607,0.00006159217,0.8177235,0.000005409241,0.0001283726,0.00009566719,0.002052663],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.4144754,"threshold_uncertainty_score":0.85856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06203925275111086,"score_gpt":0.3132001269455031,"score_spread":0.2511608741943923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}